Study identification

PURI

https://redirect.ema.europa.eu/resource/105058

EU PAS number

EUPAS104114

Study ID

105058

Official title and acronym

A two-stage, prospective observational study describing the use and effectiveness of XGEVA®/ANJIAWEI® for the prevention of skeletal related events in patients with bone metastases from solid tumors relative to ZOMETA® in the People's Republic of China (20190036)

DARWIN EU® study

No

Study countries

China

Study status

Ongoing
Research institutions and networks

Institutions

Amgen
United States
First published:
21/02/2024
Institution

Contact details

Global Development Leader Amgen Inc.

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Data analysis start date

Planned:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Amgen, Inc.
Study protocol
Initial protocol
English (2.52 MB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable